A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells
about
KIFC1: a promising chemotherapy target for cancer treatment?Drugging the addict: non-oncogene addiction as a target for cancer therapyNew approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small moleculesPrognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors.Causes and consequences of centrosome abnormalities in cancer.Centrosome-declustering drugs mediate a two-pronged attack on interphase and mitosis in supercentrosomal cancer cells.PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant gliomaGenomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.KIFC1 is a novel potential therapeutic target for breast cancer.Cell death associated with abnormal mitosis observed by confocal imaging in live cancer cells.Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cellsLet's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy.Mitotic spindle multipolarity without centrosome amplification.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues.Quantitative multi-parametric evaluation of centrosome declustering drugs: centrosome amplification, mitotic phenotype, cell cycle and deathDividing with Extra Centrosomes: A Double Edged Sword for Cancer Cells.Exclusive destruction of mitotic spindles in human cancer cells.
P2860
Q26751207-DDEB9D79-E0BF-4CDF-AEEC-2C4C862C0623Q28079559-15C196B8-F7C8-4E27-B5C3-632014A6B2B4Q28486776-F3DB33F7-7482-4F41-89D6-748C329747AEQ33671140-2BE7A3A7-0645-4CDC-89C4-D9B67F90EFCEQ33959946-76FFC121-02CF-4280-B6B3-C8EA2C56549EQ34662347-E8A43D12-D484-4F44-ABFB-59C245007528Q35741555-10C962FE-2BB5-4553-85EB-D976235AE97FQ36144711-AE248381-7A44-41D8-8D07-90AE61CC10B1Q36211466-795D7B16-6EEC-427C-9A49-5D839DC549C5Q37376022-E9C5AD49-C683-4546-81A9-873FCD61EA17Q37685815-61700B50-4DD2-43C7-80EC-4D223651DD88Q38015243-67B9225D-6B9B-4A3A-B83E-3DE92CFFBEE5Q38219034-585EB95D-58F4-494F-B6F8-33692273AB6AQ38596368-5B47627E-B0BF-426A-8B32-D71D760C7038Q38662334-9D2E8991-81E6-464C-94CA-2F7004DF3264Q38999741-C4C20CBE-0534-484B-AD62-3F7BC8B630F1Q39363632-5F51D223-9B07-4AB7-8425-7599B5525B0FQ42290806-E4FF07EA-925F-40DF-A500-883E98B2662F
P2860
A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phenanthrene derived PARP in ...... eradicating human cancer cells
@ast
A phenanthrene derived PARP in ...... eradicating human cancer cells
@en
A phenanthrene derived PARP in ...... eradicating human cancer cells
@nl
type
label
A phenanthrene derived PARP in ...... eradicating human cancer cells
@ast
A phenanthrene derived PARP in ...... eradicating human cancer cells
@en
A phenanthrene derived PARP in ...... eradicating human cancer cells
@nl
prefLabel
A phenanthrene derived PARP in ...... eradicating human cancer cells
@ast
A phenanthrene derived PARP in ...... eradicating human cancer cells
@en
A phenanthrene derived PARP in ...... eradicating human cancer cells
@nl
P2093
P2860
P356
P1433
P1476
A phenanthrene derived PARP in ...... eradicating human cancer cells
@en
P2093
Asher Castiel
Leonid Mittelman
Leonid Visochek
Malka Cohen-Armon
Shai Izraeli
P2860
P2888
P356
10.1186/1471-2407-11-412
P407
P577
2011-09-26T00:00:00Z
P5875
P6179
1005661400